Federated Investors Inc. PA increased its holdings in shares of Alkermes Plc (NASDAQ:ALKS) by 5.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 257,376 shares of the company’s stock after purchasing an additional 13,608 shares during the period. Federated Investors Inc. PA’s holdings in Alkermes were worth $9,392,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also modified their holdings of the company. Pendal Group Ltd purchased a new position in Alkermes in the first quarter valued at $82,000. Globeflex Capital L P purchased a new position in Alkermes in the first quarter valued at $148,000. Commerce Bank purchased a new position in Alkermes in the first quarter valued at $201,000. NumerixS Investment Technologies Inc increased its holdings in Alkermes by 756.9% in the fourth quarter. NumerixS Investment Technologies Inc now owns 7,712 shares of the company’s stock valued at $220,000 after buying an additional 6,812 shares in the last quarter. Finally, CIBC Asset Management Inc increased its holdings in Alkermes by 12.2% in the first quarter. CIBC Asset Management Inc now owns 8,382 shares of the company’s stock valued at $306,000 after buying an additional 910 shares in the last quarter. 97.45% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have weighed in on ALKS shares. Zacks Investment Research raised shares of Alkermes from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a report on Friday, March 29th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Alkermes in a research note on Wednesday, April 10th. TheStreet raised shares of Alkermes from a “d” rating to a “c-” rating in a research note on Tuesday, February 19th. ValuEngine raised shares of Alkermes from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Finally, Credit Suisse Group raised shares of Alkermes to a “hold” rating and set a $30.00 target price for the company in a research note on Friday, February 15th. Six equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $37.83.
In related news, Director Richard F. Pops sold 110,000 shares of the business’s stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $24.88, for a total transaction of $2,736,800.00. Following the transaction, the director now directly owns 776,433 shares in the company, valued at $19,317,653.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP David Joseph Gaffin sold 5,373 shares of the business’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $26.89, for a total transaction of $144,479.97. Following the transaction, the senior vice president now owns 53,923 shares in the company, valued at $1,449,989.47. The disclosure for this sale can be found here. Insiders have sold 196,373 shares of company stock worth $4,941,720 over the last 90 days. 4.71% of the stock is currently owned by company insiders.
ALKS stock opened at $22.65 on Thursday. The stock has a market cap of $3.52 billion, a PE ratio of -323.57 and a beta of 1.90. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.94 and a quick ratio of 2.65. Alkermes Plc has a 52 week low of $21.29 and a 52 week high of $51.70.
Alkermes (NASDAQ:ALKS) last released its earnings results on Thursday, April 25th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.06. The business had revenue of $223.10 million during the quarter, compared to analysts’ expectations of $218.84 million. Alkermes had a negative net margin of 15.86% and a negative return on equity of 2.08%. The company’s quarterly revenue was down .9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.09) earnings per share. As a group, equities analysts anticipate that Alkermes Plc will post -0.34 EPS for the current fiscal year.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
Recommended Story: Reverse Stock Split
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.